<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33035713</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0372</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>68</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current opinion in immunology</Title>
          <ISOAbbreviation>Curr Opin Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myeloid cells in sensing of tissue damage.</ArticleTitle>
        <Pagination>
          <StartPage>34</StartPage>
          <EndPage>40</EndPage>
          <MedlinePgn>34-40</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.coi.2020.08.006</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0952-7915(20)30082-0</ELocationID>
        <Abstract>
          <AbstractText>Myeloid cells are components of the innate immune system that represent the first line of defense. Tissue damage, associated with pathological conditions such as infection, cancer or autoimmunity, leads to the exposure of the intracellular content to the extracellular environment. Myeloid cells detect ligands exposed or released by dead cells through specific receptors that signal for a diversity of responses. Inflammatory responses triggered by myeloid cells after sensing tissue injury can contribute to resolution of the damage. The signaling response following dead-cell sensing by myeloid cells can contribute either to an inflammatory or a regulatory response. We review herein some representative examples of how myeloid cells react to the recognition of cell death during specific tissue damage contexts. A deep understanding of the cellular and molecular mechanisms underlying these processes would allow to improve therapeutical interventions in pathologies associated with tissue damage.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Del Fresno</LastName>
            <ForeName>Carlos</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid 28029, Spain. Electronic address: carlos.delfresno@cnic.es.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sancho</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid 28029, Spain. Electronic address: dsancho@cnic.es.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Curr Opin Immunol</MedlineTA>
        <NlmUniqueID>8900118</NlmUniqueID>
        <ISSNLinking>0952-7915</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>9</Day>
          <Hour>20</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33035713</ArticleId>
        <ArticleId IdType="pmc">PMC7538386</ArticleId>
        <ArticleId IdType="doi">10.1016/j.coi.2020.08.006</ArticleId>
        <ArticleId IdType="pii">S0952-7915(20)30082-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Del Fresno C., Cueto F.J., Sancho D.  Current Topics in Microbiology and Immunology. Springer; Berlin Heidelberg: 2019. Sensing tissue damage by myeloid C-type lectin receptors.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31974758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan G., Elbadawi M., Efferth T. Multiple cell death modalities and their key features (Review) World Acad Sci J. 2020;2:39–48. doi: 10.3892/wasj.2020.40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/wasj.2020.40</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shekarian T., Valsesia-Wittmann S., Brody J., Michallet M.C., Depil S., Caux C., Marabelle A. Pattern recognition receptors: immune targets to enhance cancer immunotherapy. Ann Oncol. 2017;28:1756–1766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28444111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matzinger P. The danger model: a renewed sense of self. Science (80-) 2002;296:301–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11951032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamberti M.J., Nigro A., Mentucci F.M., Rumie Vittar N.B., Casolaro V., Dal Col J. Dendritic cells and immunogenic cancer cell death: a combination for improving antitumor immunity. Pharmaceutics. 2020;12:256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7151083</ArticleId>
            <ArticleId IdType="pubmed">32178288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanmeerbeek I., Sprooten J., De Ruysscher D., Tejpar S., Vandenberghe P., Fucikova J., Spisek R., Zitvogel L., Kroemer G., Galluzzi L. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology. 2020;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6959434</ArticleId>
            <ArticleId IdType="pubmed">32002302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ablasser A., Chen Z.J. CGAS in action: expanding roles in immunity and inflammation. Science (80-) 2019;363</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30846571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med. 2011;208:2005–2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3182064</ArticleId>
            <ArticleId IdType="pubmed">21930765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., Lee H., Arthur C.D., White J.M., Kalinke U. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989–2003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3182061</ArticleId>
            <ArticleId IdType="pubmed">21930769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo S.R., Fuertes M.B., Corrales L., Spranger S., Furdyna M.J., Leung M.Y.K., Duggan R., Wang Y., Barber G.N., Fitzgerald K.A. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41:830–842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4384884</ArticleId>
            <ArticleId IdType="pubmed">25517615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahn J., Xia T., Rabasa Capote A., Betancourt D., Barber G.N. Extrinsic phagocyte-dependent STING signaling dictates the immunogenicity of dying cells. Cancer Cell. 2018;33:862–873.e5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6177226</ArticleId>
            <ArticleId IdType="pubmed">29706455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., Li X.D., Mauceri H., Beckett M., Darga T. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843–852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5155593</ArticleId>
            <ArticleId IdType="pubmed">25517616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Della Corte C.M., Sen T., Gay C.M., Ramkumar K., Diao L., Cardnell R.J., Rodriguez B.L., Stewart C.A., Papadimitrakopoulou V.A., Gibson L. STING pathway expression identifies NSCLC with an immune-responsive phenotype. J Thorac Oncol. 2020;15:777–791. doi: 10.1016/j.jtho.2020.01.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2020.01.009</ArticleId>
            <ArticleId IdType="pmc">PMC7202130</ArticleId>
            <ArticleId IdType="pubmed">32068166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghaffari A., Peterson N., Khalaj K., Vitkin N., Robinson A., Francis J.A., Koti M. Sting agonist therapy in combination with pd-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br J Cancer. 2018;119:440–449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6133940</ArticleId>
            <ArticleId IdType="pubmed">30046165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flood B.A., Higgs E.F., Li S., Luke J.J., Gajewski T.F. STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019;290:24–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6814203</ArticleId>
            <ArticleId IdType="pubmed">31355488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piantadosi C.A. Mitochondrial DNA, oxidants, and innate immunity. Free Radic Biol Med. 2020;152:455–461. doi: 10.1016/j.freeradbiomed.2020.01.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.01.013</ArticleId>
            <ArticleId IdType="pubmed">31958498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., Brohi K., Itagaki K., Hauser C.J. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2843437</ArticleId>
            <ArticleId IdType="pubmed">20203610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubiritova Z., Radvanszky J., Gardlik R. Cell-free nucleic acids and their emerging role in the pathogenesis and clinical management of inflammatory bowel disease. Int J Mol Sci. 2019;20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6696129</ArticleId>
            <ArticleId IdType="pubmed">31357438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puyo C.A., Earhart A., Staten N., Prince O.A., Haug C., Kollef M., Awad M. Endotracheal intubation results in acute tracheal damage induced by mtDNA/TLR9/NF-κB activity. J Leukoc Biol. 2019;105:577–587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7379990</ArticleId>
            <ArticleId IdType="pubmed">30548974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>West A.P., Khoury-Hanold W., Staron M., Tal M.C., Pineda C.M., Lang S.M., Bestwick M., Duguay B.A., Raimundo N., MacDuff D.A. Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015;520:553–557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4409480</ArticleId>
            <ArticleId IdType="pubmed">25642965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada K., Crother T.R., Karlin J., Dagvadorj J., Chiba N., Chen S., Ramanujan V.K., Wolf A.J., Vergnes L., Ojcius D.M. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36:401–414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3312986</ArticleId>
            <ArticleId IdType="pubmed">22342844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crowl J.T., Gray E.E., Pestal K., Wolkman H.E., Stetson D.B. Intracellular nucleic acid detection in autoimmunity. Annu Rev Immunol. 2017;35:313–336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6435037</ArticleId>
            <ArticleId IdType="pubmed">28142323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou R., Xie X., Li X., Qin Z., Wei C., Liu J., Luo Y. The triggers of the cGAS-STING pathway and the connection with inflammatory and autoimmune diseases. Infect Genet Evol. 2020;77</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31689545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motwani M., Pesiridis S., Fitzgerald K.A. DNA sensing by the cGAS–STING pathway in health and disease. Nat Rev Genet. 2019;20:657–674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31358977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gray E.E., Treuting P.M., Woodward J.J., Stetson D.B. Cutting edge: cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of Aicardi–Goutières syndrome. J Immunol. 2015;195:1939–1943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4546858</ArticleId>
            <ArticleId IdType="pubmed">26223655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas J.O. HMG 1 and 2: architectural DNA-binding proteins. Biochem Soc Trans. 2001:395–401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11497996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D., Kang R., Livesey K.M., Cheh C.W., Farkas A., Loughran P., Hoppe G., Bianchi M.E., Tracey K.J., Zeh H.J. Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010;190:881–892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2935581</ArticleId>
            <ArticleId IdType="pubmed">20819940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191–195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12110890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li G., Liang X., Lotze M.T. HMGB1: the central cytokine for all lymphoid cells. Front Immunol. 2013;4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3602962</ArticleId>
            <ArticleId IdType="pubmed">23519706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17704786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorgulho C.M., Romagnoli G.G., Bharthi R., Lotze M.T. Johnny on the spot-chronic inflammation is driven by HMGB1. Front Immunol. 2019;10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6660267</ArticleId>
            <ArticleId IdType="pubmed">31379812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haruna M., Hirata M., Iwahori K., Kanazawa T., Yamamoto Y., Goto K., Kawashima A., Morimoto-Okazawa A., Funaki S., Shintani Y. Docetaxel upregulates HMGB1 levels in non-small cell lung cancer. Biol Pharm Bull. 2020;43:399–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32115500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Z., Chen M., Wei M., Lu B., Wu X., Wang Z., Ji L. Liver inflammatory injury initiated by DAMPs-TLR4-MyD88/TRIF-NFκB signaling pathway is involved in monocrotaline-induced HSOS. Toxicol Sci. 2019;172:385–397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31504964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun L., Li M., Ma X., Zhang L., Song J., Lv C., He Y. Inhibiting high mobility group box-1 reduces early spinal cord edema and attenuates astrocyte activation and aquaporin-4 expression after spinal cord injury in rats. J Neurotrauma. 2019;36:421–435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29929431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng L., Li L., Lu S., Li K., Su Z., Wang Y., Fan X., Li X., Zhao G. The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways. Mol Immunol. 2018;94:7–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29241031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H., Guan B., Wang B., Pu H., Bai X., Chen X., Liu J., Li C., Qiu J., Yang D. Glycyrrhizin prevents hemorrhagic transformation and improves neurological outcome in ischemic stroke with delayed thrombolysis through targeting peroxynitrite-mediated HMGB1 signaling. Transl Stroke Res. 2019;11:967–982. doi: 10.1007/s12975-019-00772-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12975-019-00772-1</ArticleId>
            <ArticleId IdType="pubmed">31872339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng L., Zhu Q., Xu C., Li M., Li H., Yi P.Q., Xu F.F., Cao L., Chen J.Y. Glycyrrhizin mitigates radiation-induced acute lung injury by inhibiting the HMGB1/TLR4 signalling pathway. J Cell Mol Med. 2020;24:214–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6933400</ArticleId>
            <ArticleId IdType="pubmed">31657123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gardella S., Andrei C., Ferrera D., Lotti L.V., Torrisi M.R., Bianchi M.E., Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002;3:995–1001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1307617</ArticleId>
            <ArticleId IdType="pubmed">12231511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P., Xin X., Fang L., Jiang H., Xu X., Su X., Shi Y. HMGB1 mediates Aspergillus fumigatus-induced inflammatory response in alveolar macrophages of COPD mice via activating MyD88/NF-κB and syk/PI3K signalings. Int Immunopharmacol. 2017;53:125–132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29078091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamasaki S., Ishikawa E., Sakuma M., Hara H., Ogata K., Saito T. Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat Immunol. 2008;9:1179–1188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18776906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka M., Saka-Tanaka M., Ochi K., Fujieda K., Sugiura Y., Miyamoto T., Kohda H., Ito A., Miyazawa T., Matsumoto A. C-type lectin Mincle mediates cell death-triggered inflammation in acute kidney injury. J Exp Med. 2020;217</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7596812</ArticleId>
            <ArticleId IdType="pubmed">32797195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y., Xu L., Li B., Guo Z.N., Hu Q., Guo Z., Tang J., Chen Y., Zhang Y., Tang J. Macrophage-inducible C-type lectin/spleen tyrosine kinase signaling pathway contributes to neuroinflammation after subarachnoid hemorrhage in rats. Stroke. 2015;46:2277–2286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4519357</ArticleId>
            <ArticleId IdType="pubmed">26138128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.W., Roh Y.S., Jeong H., Yi H.K., Lee M.H., Lim C.W., Kim B. Spliceosome-associated protein 130 exacerbates alcohol-induced liver injury by inducing NLRP3 inflammasome–mediated IL-1β in mice. Am J Pathol. 2018;188:967–980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29355515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong W., Guo K., Zheng T., Fang M., Xie H., Li W., Hong Z., Ren H., Gu G., Wang G. Preliminary exploration of the potential of spliceosome-associated protein 130 for predicting disease severity in Crohn’s disease. Ann N Y Acad Sci. 2020;1462:128–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31583714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N’Diaye M., Brauner S., Flytzani S., Kular L., Warnecke A., Adzemovic M.Z., Piket E., Min J.H., Edwards W., Mela F. C-type lectin receptors Mcl and Mincle control development of multiple sclerosis-like neuroinflammation. J Clin Invest. 2020;130:838–852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6994148</ArticleId>
            <ArticleId IdType="pubmed">31725411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Z., Abrams S.T., Alhamdi Y., Toh J., Yu W., Wang G., Toh C.H. Circulating histones are major mediators of multiple organ dysfunction syndrome in acute critical illnesses. Crit Care Med. 2019;47:E677–E684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31162199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu J., Zhang X., Monestier M., Esmon N.L., Esmon C.T. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol. 2011;187:2626–2631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3159755</ArticleId>
            <ArticleId IdType="pubmed">21784973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westman J., Papareddy P., Dahlgren M.W., Chakrakodi B., Norrby-Teglund A., Smeds E., Linder A., Mörgelin M., Johansson-Lindbom B., Egesten A. Extracellular histones induce chemokine production in whole blood ex vivo and leukocyte recruitment in vivo. PLoS Pathog. 2015;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4672907</ArticleId>
            <ArticleId IdType="pubmed">26646682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westman J., Smeds E., Johansson L., Mörgelin M., Olin A.I., Malmström E., Linder A., Herwald H. Treatment with p33 curtails morbidity and mortality in a histone-induced murine shock model. J Innate Immun. 2014;6:819–830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6741576</ArticleId>
            <ArticleId IdType="pubmed">24942226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westman J., Chakrakodi B., Snäll J., Mörgelin M., Madsen M.B., Hyldegaard O., Neumann A., Frick I.M., Norrby-Teglund A., Björck L. Protein SIC secreted from Streptococcus pyogenes forms complexes with extracellular histones that boost cytokine production. Front Immunol. 2018;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5827136</ArticleId>
            <ArticleId IdType="pubmed">29520265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian Y., Charles E.J., Yan Z., Wu D., French B.A., Kron I.L., Yang Z. The myocardial infarct-exacerbating effect of cell-free DNA is mediated by the high-mobility group box 1–receptor for advanced glycation end products–Toll-like receptor 9 pathway. J Thorac Cardiovasc Surg. 2019;157:2256–2269.e3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6450791</ArticleId>
            <ArticleId IdType="pubmed">30401529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang H., Tohme S., Al-Khafaji A.B., Tai S., Loughran P., Chen L., Wang S., Kim J., Billiar T., Wang Y. Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology. 2015;62:600–614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4515210</ArticleId>
            <ArticleId IdType="pubmed">25855125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., Parroche P., Drabic S., Golenbock D., Sirois C. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8:487–496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17417641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanai H., Ban T., Wang Z., Choi M.K., Kawamura T., Negishi H., Nakasato M., Lu Y., Hangai S., Koshiba R. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 2009;462:99–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19890330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersson U., Ottestad W., Tracey K.J. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med. 2020;26:42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7203545</ArticleId>
            <ArticleId IdType="pubmed">32380958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai J.J., Cruz F.M., Rock K.L. Immune sensing of cell death through recognition of histone sequences by C-type lectin-receptor-2d causes inflammation and tissue injury. Immunity. 2020;52:123–135.e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6962543</ArticleId>
            <ArticleId IdType="pubmed">31859049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahrens S., Zelenay S., Sancho D., Hanč P., Kjær S., Feest C., Fletcher G., Durkin C., Postigo A., Skehel M. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity. 2012;36:635–645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22483800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J.-G., Czabotar P.E., Policheni A.N., Caminschi I., Wan S.S., Kitsoulis S., Tullett K.M., Robin A.Y., Brammananth R., van Delft M.F. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity. 2012;36:646–657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22483802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cueto F.J., del Fresno C., Sancho D. DNGR-1, a dendritic cell-specific sensor of tissue damage that dually modulates immunity and inflammation. Front Immunol. 2020;10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7018937</ArticleId>
            <ArticleId IdType="pubmed">32117205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancho D., Joffre O.P., Keller A.M., Rogers N.C., Martínez D., Hernanz-Falcón P., Rosewell I., Reis e Sousa C. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature. 2009;458:899–903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2671489</ArticleId>
            <ArticleId IdType="pubmed">19219027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iborra S., Izquierdo H.M., Sancho D. Th DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice. J Clin Invest. 2012;122:1628–1643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3336985</ArticleId>
            <ArticleId IdType="pubmed">22505455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zelenay S., Keller A.M., Whitney P.G., Schraml B.U., Deddouche S., Rogers N.C., Schulz O., Sancho D., Reis E., Sousa C. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. J Clin Invest. 2012;122:1615–1627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3336984</ArticleId>
            <ArticleId IdType="pubmed">22505458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>del Fresno C., Saz-Leal P., Enamorado M., Wculek S.K., Martínez-Cano S., Blanco-Menéndez N., Schulz O., Gallizioli M., Miró-Mur F., Cano E. DNGR-1 in dendritic cells limits tissue damage by dampening neutrophil recruitment. Science (80-) 2018;362:351–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30337411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soares M.P., Teixeira L., Moita L.F. Disease tolerance and immunity in host protection against infection. Nat Rev Immunol. 2017;17:83–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28044057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neumann K., Castiñeiras-Vilariño M., Höckendorf U., Hannesschläger N., Lemeer S., Kupka D., Meyermann S., Lech M., Anders H.J., Kuster B. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Immunity. 2014;40:389–399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24631154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di S., Singh N.P., Ginwala R., Huang X., Philip R., Nagarkatti M., Nagarkatti P., Neumann K., Ruland J., Andrews A.M. Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity. Sci Rep. 2017;7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5457463</ArticleId>
            <ArticleId IdType="pubmed">28578388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li K., Neumann K., Duhan V., Namineni S., Hansen A.L., Wartewig T., Kurgyis Z., Holm C.K., Heikenwalder M., Lang K.S. The uric acid crystal receptor Clec12A potentiates type I interferon responses. Proc Natl Acad Sci U S A. 2019;116:18544–18549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6744871</ArticleId>
            <ArticleId IdType="pubmed">31451663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>del Fresno C., Iborra S., Saz-Leal P., Martínez-López M., Sancho D. Flexible signaling of Myeloid C-type lectin receptors in immunity and inflammation. Front Immunol. 2018;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5932189</ArticleId>
            <ArticleId IdType="pubmed">29755458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seifert L., Werba G., Tiwari S., Giao Ly N.N., Alothman S., Alqunaibit D., Avanzi A., Barilla R., Daley D., Greco S.H. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature. 2016;532:245–249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4833566</ArticleId>
            <ArticleId IdType="pubmed">27049944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iborra S., Martínez-López M., Cueto F.J., Conde-Garrosa R., Del Fresno C., Izquierdo H.M., Abram C.L., Mori D., Campos-Martín Y., Reguera R.M. Leishmania uses Mincle to target an inhibitory ITAM signaling pathway in dendritic cells that dampens adaptive immunity to infection. Immunity. 2016;45:788–801. doi: 10.1016/j.immuni.2016.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.09.012</ArticleId>
            <ArticleId IdType="pmc">PMC5074365</ArticleId>
            <ArticleId IdType="pubmed">27742545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G.-Y., Tang J., Zheng P., Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science (80-) 2009;323:1722–1725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2765686</ArticleId>
            <ArticleId IdType="pubmed">19264983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toubai T., Rossi C., Oravecz-wilson K., Zajac C., Liu C., Braun T., Fujiwara H., Wu J., Sun Y., Brabbs S. Siglec-G represses DAMP-mediated effects on T cells. JCI Insight. 2017;2:1–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5518560</ArticleId>
            <ArticleId IdType="pubmed">28724800</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
